CURATE.AI Optimized Modulation for Multiple Myeloma

Summary

Clinical trial applying CURATE.AI, a Phenotypic Precision Medicine (PPM) platform, to Bortezomib, Thalidomide, Cyclophosphamide and Lenalidomide dosing in multiple myeloma patients to show improvement in response.

Conditions

• Multiple Myeloma

Interventions

DRUG

Bortezomib

Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team

DRUG

Cyclophosphamide

Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team

DRUG

Dexamethasone

Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team

OTHER

CURATE.AI-Guided dosage modulation

CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen

DRUG

Thalidomide

Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team

DRUG

Bortezomib

Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team

DRUG

Cyclophosphamide

Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.

DRUG

Thalidomide

Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.

DRUG

Dexamethasone

40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care

DRUG

Lenalidomide

Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team

DRUG

Lenalidomide

Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.

Sponsors & Collaborators

• National University of Singapore

  collaborator OTHER

• National University Hospital, Singapore

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

21 Years

Max Age

99 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-09-10

Primary Completion

2025-09-10

Completion

2025-09-10

Countries

• Singapore

Study Locations